<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">nefr</journal-id><journal-title-group><journal-title xml:lang="ru">Нефрология</journal-title><trans-title-group xml:lang="en"><trans-title>Nephrology (Saint-Petersburg)</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1561-6274</issn><issn pub-type="epub">2541-9439</issn><publisher><publisher-name>Pavlov First Saint-Petersburg State Medical University</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.24884/1561-6274-2008-12-2-52-55</article-id><article-id custom-type="elpub" pub-id-type="custom">nefr-1060</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ. КЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES. CLINICAL INVESTIGATIONS</subject></subj-group></article-categories><title-group><article-title>ГЕНЕТИЧЕСКАЯ ДЕТЕРМИНИРОВАННОСТЬ ПОВЫШЕНИЯ ТРОМБОГЕННОГО ПОТЕНЦИАЛА КРОВИ У БОЛЬНЫХ ХРОНИЧЕСКИМ ГЛОМЕРУЛОНЕФРИТОМ</article-title><trans-title-group xml:lang="en"><trans-title>GENETICALY DETERMINED ELEVATION OF THROMBOGENIC POTENTIAL OF BLOOD IN PATIENTS WITH CHRONIC GLOMERULONEPHRITIS</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сибирева</surname><given-names>О. Ф.</given-names></name><name name-style="western" xml:lang="en"><surname>Simbirtseva</surname><given-names>O. F.</given-names></name></name-alternatives><bio xml:lang="ru"><p>кафедра госпитальной терапии с курсом физической реабилитации и спортивной медицины</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Хитринская</surname><given-names>Е. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Khitrinskaya</surname><given-names>E. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>кафедра госпитальной терапии с курсом физической реабилитации и спортивной медицины</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Иванчук</surname><given-names>И. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Ivanchuk</surname><given-names>I. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>кафедра госпитальной терапии с курсом физической реабилитации и спортивной медицины</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Калюжин</surname><given-names>В. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kalyuzhin</surname><given-names>V. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>кафедра госпитальной терапии с курсом физической реабилитации и спортивной медицины </p><p>Томск, ГОУ ВПО «Сибирский государствен­ный медицинский университет», тел.:(388-2) 64-66-83</p></bio><email xlink:type="simple">kalyzhinvv@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Зибницкая</surname><given-names>Л. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Zibnitskaya</surname><given-names>L. I.</given-names></name></name-alternatives><bio xml:lang="ru"/><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ткалич</surname><given-names>Л. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Tkalich</surname><given-names>L. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>кафедра госпитальной терапии с курсом физической реабилитации и спортивной медицины</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Калюжина</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kalyuzhina</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>кафедра госпитальной терапии с курсом физической реабилитации и спортивной медицины</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">Сибирский государствен­ный медицинский университет, г. Томск<country>Россия</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2008</year></pub-date><pub-date pub-type="epub"><day>10</day><month>02</month><year>2008</year></pub-date><volume>12</volume><issue>2</issue><fpage>52</fpage><lpage>55</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Сибирева О.Ф., Хитринская Е.Ю., Иванчук И.И., Калюжин В.В., Зибницкая Л.И., Ткалич Л.М., Калюжина Е.В., 2008</copyright-statement><copyright-year>2008</copyright-year><copyright-holder xml:lang="ru">Сибирева О.Ф., Хитринская Е.Ю., Иванчук И.И., Калюжин В.В., Зибницкая Л.И., Ткалич Л.М., Калюжина Е.В.</copyright-holder><copyright-holder xml:lang="en">Simbirtseva O.F., Khitrinskaya E.Y., Ivanchuk I.I., Kalyuzhin V.V., Zibnitskaya L.I., Tkalich L.M., Kalyuzhina E.V.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://journal.nephrolog.ru/jour/article/view/1060">https://journal.nephrolog.ru/jour/article/view/1060</self-uri><abstract><p>ЦЕЛЬ ИССЛЕДОВАНИЯ. Изучение у больных хроническим гломерулонефритом частоты встречаемости и клинико-патогенетического значения протромботических генотипов, имеющих среди гематогенных тромбофилий наибольшую клиническую и прогностическую значимость. ПАЦИЕНТЫ И МЕТОДЫ. Обследовали 180 больных хроническим гломерулонефритом (средний возраст 22,3±0,8 года). Наряду с полным клиническим и инструментальным обследованием, принятым в специализированной нефрологической клинике, с помощью метода полимеразной цепной реакции выполнена диагностика однонуклеотидной замены С677Т в гене метилентетрагидрофолатредуктазы, точечной мутации гена фактора V свертывания крови, а также мутации G20210A в 3’-нетранслируемой области гена фактора II свертывания крови (образцы геномной ДНК получали из лейкоцитов периферической крови методом фенол-хлороформной экстракции). В контрольную группу вошло 100 здоровых лиц со сходными демографическими характеристиками. РЕЗУЛЬТАТЫ. Установлено, что изучаемые протромбогенные мутации встречаются у больных хроническим гломерулонефритом с большей частотой, чем среди здоровых лиц. Эти нуклеотидные замены ассоциированы с развитием у больных хроническим гломерулонефритом гиперкоагуляционного синдрома и повышением риска почечной недостаточности. ЗАКЛЮЧЕНИЕ. Результаты настоящего исследования свидетельствуют о том, что по меньшей мере у части больных хроническим гломерулонефритом повышение тромбогенного потенциала крови генетически детерминировано.</p></abstract><trans-abstract xml:lang="en"><p>THE AIM of the investigation was to study the occurrence and clinic-pathogenetic value of prothrombotic genotypes which are of the greatest clinical and prognosic value among hematogenic thrombophilias. PATIENTS AND METHODS. Examination was performed in 180 patients with chronic glomerulonephritis (mean age 22.3±0.8 years). In addition to complete clinical and instrumental examination used at the specialized nephrological clinic, with the help of polymerase chain reaction the diagnosis of a single nucleotide change of C677T in the gene of methylenetetrahydrofolate reductase, punctated gene mutation of V factor of blood coagulation, and G20210A mutation in 3’ nontranslated area of gene of II factor of blood coagulation (samples of genomic DNA was obtained from peripheral blood leukocytes by the method of phenol-chloroform extraction). The control group included 100 healthy subjects with similar demographic characteristics. RESULTS. It was found thst protrombogenic mutations under study can be found in patients with chronic glomerulonephritis more often than among healthy subjects. These nucleotide changes are associated with the development of hypercoagulation syndrome and high risk of renal failure in patients with chronic glomerulonephritis. CONCLUSION. The results of thisinvestigation show that at least part of the patients with chronic glomerulonephritis have genetically determined elevation of thrombogenic potential of blood.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>хронический гломерулонефрит</kwd><kwd>протромботические генотипы</kwd><kwd>распространенность</kwd></kwd-group><kwd-group xml:lang="en"><kwd>chronic glomerulonephritis</kwd><kwd>prothrombotic genotypes</kwd><kwd>occurrence</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Тареева ИЕ, Мухин НА. Механизмы прогрессирования нефрита. В: Тареева ИЕ, ред. Нефрология: руководство для врачей. Том. 2. Медицина, М., 2000; 20-28</mixed-citation><mixed-citation xml:lang="en">Тареева ИЕ, Мухин НА. Механизмы прогрессирования нефрита. В: Тареева ИЕ, ред. Нефрология: руководство для врачей. Том. 2. Медицина, М., 2000; 20-28</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Рябов СИ. Нефрология: руководство для врачей. СпецЛит, СПб., 2000; 672</mixed-citation><mixed-citation xml:lang="en">Рябов СИ. Нефрология: руководство для врачей. СпецЛит, СПб., 2000; 672</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Шулутко БИ. Нефрология 2002. Современное состояние проблемы. Ренкор, СПб., 2002; 780</mixed-citation><mixed-citation xml:lang="en">Шулутко БИ. Нефрология 2002. Современное состояние проблемы. Ренкор, СПб., 2002; 780</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Глессок РД, Бреннер БМ. Иммунопатогенетические механизмы повреждения почек. В: Браунвальд Е, Иссельбахер КДж, Петерсдорф РГ, ред. Внутренние болезни.Книга. 6. Медицина, М., 1995; 282-289</mixed-citation><mixed-citation xml:lang="en">Глессок РД, Бреннер БМ. Иммунопатогенетические механизмы повреждения почек. В: Браунвальд Е, Иссельбахер КДж, Петерсдорф РГ, ред. Внутренние болезни.Книга. 6. Медицина, М., 1995; 282-289</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Спиридонова МГ, Степанов ВА, Пузырев ВП. О роли полиморфных вариантов гена 5,10–метилентетрагидрофо-латредуктазы (MTHFR) в патогенезе сердечно-сосудистых заболеваний. Клин мед 2001; (2): 10-16</mixed-citation><mixed-citation xml:lang="en">Спиридонова МГ, Степанов ВА, Пузырев ВП. О роли полиморфных вариантов гена 5,10–метилентетрагидрофо-латредуктазы (MTHFR) в патогенезе сердечно-сосудистых заболеваний. Клин мед 2001; (2): 10-16</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Rosenberg N, Murata M, Ikeda Y et al. The Frequent 5,10-methylenetetrahydrofolate reductase C677T polymorphism is associated with a common haplotype in whites, japanese, and africans. Am J Hum Genet 2002; 71: 758-762</mixed-citation><mixed-citation xml:lang="en">Rosenberg N, Murata M, Ikeda Y et al. The Frequent 5,10-methylenetetrahydrofolate reductase C677T polymorphism is associated with a common haplotype in whites, japanese, and africans. Am J Hum Genet 2002; 71: 758-762</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Добронравов ВА, Голубев РВ. Гипергомоцистеинемия – фактор риска сердечно-сосудистых поражений у диализных больных и в общей популяции. Нефрология 2004; (2): 44-49</mixed-citation><mixed-citation xml:lang="en">Добронравов ВА, Голубев РВ. Гипергомоцистеинемия – фактор риска сердечно-сосудистых поражений у диализных больных и в общей популяции. Нефрология 2004; (2): 44-49</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Fodinger M, Mannhalter C, Wolfl G et al. Mutation (677 С to T) in the methyltetrahydrofolate reductase gene aggravates hyperhomocysteinemia in hemodialysis patients. Kidney Int 1997; 52: 517-523</mixed-citation><mixed-citation xml:lang="en">Fodinger M, Mannhalter C, Wolfl G et al. Mutation (677 С to T) in the methyltetrahydrofolate reductase gene aggravates hyperhomocysteinemia in hemodialysis patients. Kidney Int 1997; 52: 517-523</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Момот АП. Патология гемостаза. Принципы и алгоритмы клинико-лабораторной диагностики. Форма Т, СПб., 2006; 208</mixed-citation><mixed-citation xml:lang="en">Момот АП. Патология гемостаза. Принципы и алгоритмы клинико-лабораторной диагностики. Форма Т, СПб., 2006; 208</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Насонов ЕЛ. Антифосфолипидный синдром. Литтерра, М., 2004; 440</mixed-citation><mixed-citation xml:lang="en">Насонов ЕЛ. Антифосфолипидный синдром. Литтерра, М., 2004; 440</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Irish A. The factor V Leiden mutation and risk of renal vein thrombosis in patients with nephrotic syndrome. Nephrol Dial Transplant 1997; 12: 1680-1683</mixed-citation><mixed-citation xml:lang="en">Irish A. The factor V Leiden mutation and risk of renal vein thrombosis in patients with nephrotic syndrome. Nephrol Dial Transplant 1997; 12: 1680-1683</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Aucella F, Margaglione M, Grandone E et al. On behalf of The Genetic Polymorphisms in Dialysis Study Group. The C677T methylenetetrahydrofolate reductase gene mutation does not influence cardiovascular risk in the dialysis population: results of a multicentre prospective study. Nephrol Dial Transplant 2004; 20 (2): 382-386</mixed-citation><mixed-citation xml:lang="en">Aucella F, Margaglione M, Grandone E et al. On behalf of The Genetic Polymorphisms in Dialysis Study Group. The C677T methylenetetrahydrofolate reductase gene mutation does not influence cardiovascular risk in the dialysis population: results of a multicentre prospective study. Nephrol Dial Transplant 2004; 20 (2): 382-386</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Haviv YS, Shpichinetsky V, Goldschmidt N et al. The common mutations C677T and A1298C in the human methylenetetrahydrofolate reductase gene are associated with hyperhomocysteinemia and cardiovascular disease in hemodialysis patients. Nephron 2002; 92: 120-126</mixed-citation><mixed-citation xml:lang="en">Haviv YS, Shpichinetsky V, Goldschmidt N et al. The common mutations C677T and A1298C in the human methylenetetrahydrofolate reductase gene are associated with hyperhomocysteinemia and cardiovascular disease in hemodialysis patients. Nephron 2002; 92: 120-126</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Morimoto K, Haneda T, Okamoto K et al. Methylenetetrahydrofolate reductase gene polymorphism, hyperhomocysteinemia, and cardiovascular diseases in chronic hemodialysis patients. Nephron 2002; 90: 43-50</mixed-citation><mixed-citation xml:lang="en">Morimoto K, Haneda T, Okamoto K et al. Methylenetetrahydrofolate reductase gene polymorphism, hyperhomocysteinemia, and cardiovascular diseases in chronic hemodialysis patients. Nephron 2002; 90: 43-50</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Quintana LF, Cofan F, Reverte JC et al. Renal cortical necrosis after kidney transplantation associated with the prothrombin 20210A mutation. Nephrol Dial Transplant 2006; 21 (5): 1455-1456</mixed-citation><mixed-citation xml:lang="en">Quintana LF, Cofan F, Reverte JC et al. Renal cortical necrosis after kidney transplantation associated with the prothrombin 20210A mutation. Nephrol Dial Transplant 2006; 21 (5): 1455-1456</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Irish A. Hypercoagulability in renal transplant recipients. Identifying patients at risk of renal allograft thrombosis and evaluating strategies for prevention. Am J Cardiovasc Drugs 2004; 4: 139-149</mixed-citation><mixed-citation xml:lang="en">Irish A. Hypercoagulability in renal transplant recipients. Identifying patients at risk of renal allograft thrombosis and evaluating strategies for prevention. Am J Cardiovasc Drugs 2004; 4: 139-149</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Heidenreich S, Junker R, Wolters H et al. Outcome of kidney transplantation in patients with inherited thrombophilia: data of a prospective study. J Am Soc Nephrol 2003; 14: 234-239</mixed-citation><mixed-citation xml:lang="en">Heidenreich S, Junker R, Wolters H et al. Outcome of kidney transplantation in patients with inherited thrombophilia: data of a prospective study. J Am Soc Nephrol 2003; 14: 234-239</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Heidenreich S, Junker R, Wolters H. Outcome of kidney transplantation in patients with inherited thrombophilia: data of a prospective study. J Am Soc Nephrol 2003; 14 (1): 234-239</mixed-citation><mixed-citation xml:lang="en">Heidenreich S, Junker R, Wolters H. Outcome of kidney transplantation in patients with inherited thrombophilia: data of a prospective study. J Am Soc Nephrol 2003; 14 (1): 234-239</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Zychma MJ, Gumprecht J, Grzeszczak W, Zukowska-Szczechowska E. Methylenetetrahydrofolate reductase gene C677T polymorphism, plasma homocysteine and folate in end-stage renal disease dialysis and non-dialysis patients. Nephron 2002; 92: 235-239</mixed-citation><mixed-citation xml:lang="en">Zychma MJ, Gumprecht J, Grzeszczak W, Zukowska-Szczechowska E. Methylenetetrahydrofolate reductase gene C677T polymorphism, plasma homocysteine and folate in end-stage renal disease dialysis and non-dialysis patients. Nephron 2002; 92: 235-239</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Winkelmayer WC, Kramar R, Sunder-Plassmann G, Fцdinger M. Effects of single-nucleotide polymorphisms in MTHFR and MTRR on mortality and allograft loss in kidney transplant recipients. Kidney Int 2005; 68: 2857-2862</mixed-citation><mixed-citation xml:lang="en">Winkelmayer WC, Kramar R, Sunder-Plassmann G, Fцdinger M. Effects of single-nucleotide polymorphisms in MTHFR and MTRR on mortality and allograft loss in kidney transplant recipients. Kidney Int 2005; 68: 2857-2862</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Kim RJ, Becker RC. Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: a meta-analysis of published studies. Am Heart J 2003; 146: 948-957</mixed-citation><mixed-citation xml:lang="en">Kim RJ, Becker RC. Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: a meta-analysis of published studies. Am Heart J 2003; 146: 948-957</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Kabukcu S. The frequency of factor V Leiden and concomitance of factor V Leiden with prothrombin G20210A mutation and methylene tetrahydrofolate reductase C677T gene mutation in healthy population of denizli. Clinical and Applied Thrombosis / Hemostasis 2007; 13 (2): 166-171</mixed-citation><mixed-citation xml:lang="en">Kabukcu S. The frequency of factor V Leiden and concomitance of factor V Leiden with prothrombin G20210A mutation and methylene tetrahydrofolate reductase C677T gene mutation in healthy population of denizli. Clinical and Applied Thrombosis / Hemostasis 2007; 13 (2): 166-171</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
